Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Clinical trial NCT04487106 · COMPLETED

Trial details

NCT number: NCT04487106
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome

Start date: 2020-07-21
Primary completion: 2023-02-09
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.